T. Rowe Price Associates’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $221M | Sell |
|
|||||
|
2025
Q2 | $161M | Buy |
|
|||||
|
2025
Q1 | $171M | Sell |
|
|||||
|
2024
Q4 | $277M | Buy |
|
|||||
|
2024
Q3 | $253M | Buy |
|
|||||
|
2024
Q2 | $197M | Buy |
|
|||||
|
2024
Q1 | $179M | Buy |
|
|||||
|
2023
Q4 | $107M | Buy |
|
|||||
|
2023
Q3 | $76.7M | Buy |
|
|||||
|
2023
Q2 | $25.8M | Buy |
|
|||||
|
2023
Q1 | $672K | Sell |
|
|||||
|
2022
Q4 | $951K | Sell |
|
|||||
|
2022
Q3 | $1.21M | Buy |
|
|||||
|
2022
Q2 | $1.01M | Buy |
|
|||||
|
2022
Q1 | $825K | Sell |
|
|||||
|
2021
Q4 | $2.18M | Buy |
|
|||||
|
2021
Q3 | $1.39M | Buy |
|
|||||
|
2021
Q2 | $1.24M | Buy |
|
|||||
|
2021
Q1 | $747K | Sell |
|
|||||
|
2020
Q4 | $1.14M | Sell |
|
|||||
|
2020
Q3 | $1.35M | Hold |
|
|||||
|
2020
Q2 | $1.51M | Buy |
|
|||||
|
2020
Q1 | $418K | Sell |
|
|||||
|
2019
Q4 | $906K | Sell |
|
|||||
|
2019
Q3 | $786K | Sell |
|
|||||
|
2019
Q2 | $12.2M | Buy |
|
|||||
|
2019
Q1 | $11.1M | Buy |
|
|||||
|
2018
Q4 | $13M | Buy |
|
|||||
|
2018
Q3 | $12.4M | Buy |
|